Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.46 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.46 |
| ▸ | APLNR | P35414 | 2/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | NMT2 | O60551 | 2/20 | 0.40 |
| ▸ | NMT1 | P30419 | 2/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30562642 | 0.99 | SLC6A5 (0.52) | SLC6A5ITGB3ITGA2BSLC15A2APLNR | |
| SCHEMBL30716920 | 0.92 | SLC6A5 (0.52) | SLC6A5ITGB3ITGA2BSLC15A2APLNR | |
| SCHEMBL29941942 | 0.92 | SLC6A5 (0.52) | SLC6A5ITGB3ITGA2BSLC15A2APLNR | |
| SCHEMBL322731 | 0.89 | SLC6A5 (0.52) | SLC6A5ITGB3ITGA2BSLC15A2APLNR | |
| SCHEMBL1163474 | 0.89 | SLC6A5 (0.52) | SLC6A5ITGB3ITGA2BSLC15A2APLNR | |
| SCHEMBL31138844 | 0.88 | SLC6A5 (0.50) | SLC6A5ITGB3ITGA2BSLC15A2APLNR | |
| SCHEMBL30562699 | 0.88 | APLNR (0.53) | APLNRNOD1 | |
| SCHEMBL29942896 | 0.88 | APLNR (0.53) | APLNRNOD1 | |
| SCHEMBL29467847 | 0.87 | SLC6A5 (0.49) | SLC6A5ITGB3ITGA2BSLC15A2APLNR | |
| SCHEMBL17844297 | 0.86 | SLC6A5 (0.52) | SLC6A5ITGB3ITGA2BAPLNRNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110769862-B | Non-viral gene delivery agents comprising Lipopeptide (LP) compounds | 莫纳什大学 | 2023-09-12 | — | — | CN | disclosed |
| US-11446393-B2 | Non-viral gene delivery agent comprising lipopeptide (LP) compounds | MONASH UNIVERSITY (AU) | 2022-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11446393-B2 | Non-viral gene delivery agent comprising lipopeptide (LP) compounds | LNPEP, TLR9, LPXN | SLC6A5 4189/4885ITGB3 4585/4885ITGA2B 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.